Free Delivery Over $100
|
|
|||
|
||||
OverviewFrom a capital market perspective, the author analyzes Merger and Acquisitions transactions (M&A) and in-licensings in the pharmaceutical industry between 1998 and 2012. Utilizing the event study methodology, the volume shows that M&A experiences significant, negative cumulative average abnormal returns whereas in-licensings are able to create value. But what are the underlying value drivers which make a deal a success or a failure story? The author derives significant innovative determinants of success for both strategies. Full Product DetailsAuthor: Dirk Schiereck , Heiko SchönPublisher: Peter Lang AG Imprint: Peter Lang AG Edition: New edition Volume: 15 Weight: 0.360kg ISBN: 9783631663813ISBN 10: 3631663811 Pages: 201 Publication Date: 28 September 2015 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Out of stock  The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available. Table of ContentsContents: The Pharmaceutical Industry and its Paradigm Shift – The Pharmaceutical Industry and Mergers & Acquisitions – Value Creation in Pharmaceutical M&A and its underlying Value Drivers – The Pharmaceutical Industry and Alliances – Value Creation in Pharmaceutical In-licensings and its underlying Value Drivers – M&A versus In-licensing.ReviewsAuthor InformationHeiko Schön studied international business administration at Wiesbaden Business School. He was scholar of the German National Merit Foundation (sdw), he owns an Executive MBA from the University of Münster and earned his PhD at the University of Darmstadt. He brings in 10 years of experience in the pharmaceutical and chemical industry. Tab Content 6Author Website:Countries AvailableAll regions |
||||
